ClinicalTrials.gov
ClinicalTrials.gov Menu

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00658359
Recruitment Status : Completed
First Posted : April 15, 2008
Results First Posted : February 23, 2018
Last Update Posted : February 23, 2018
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will follow transplant patients through Month 36 posttransplant. Patients will continue their study medications that were previously assigned.

Condition or disease Intervention/treatment Phase
Kidney Transplantation Drug: Cyclosporine Drug: CP-690,550 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 178 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Actual Study Start Date : August 2008
Actual Primary Completion Date : March 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Treatment Arm 1
Treatment Arm 1 will also receive standard of care medications
Drug: Cyclosporine
Standard of care

Experimental: Treatment Arm 2
Treatment Arm 2 will also receive standard of care medications
Drug: CP-690,550
CP-690,550 tablets dosed BID Months 12-72

Experimental: Treatment Arm 3
Treatment Arm 3 will also receive standard of care medications
Drug: CP-690,550
CP-690,550 tablets dosed BID Months 12-72




Primary Outcome Measures :
  1. Kaplan-Meier Analysis of Percentage of Participants With Clinically Significant Infection by Visit [ Time Frame: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]
    Clinically significant infection was defined as the presence of documented infection confirmed by culture, biopsy, genomic, or serologic findings post-randomization and requiring hospitalization or parenteral anti-infective treatment, or otherwise deemed significant by the investigator. The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits.

  2. Percentage of Participants With Malignancies [ Time Frame: Months 12 through 72. ]
    All treatment-emergent malignancies in Study A3921050 were included as collected on the Malignancy Case Report Form page.

  3. Least Squares Means of Measured Glomerular Filtration Rate (GFR) (Iohexol Serum Clearance in Milliliters Per Minute [mL/Min]) [ Time Frame: Month 36 ]
    Glomerular filtration rate (GFR): an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous (IV) bolus over 5 minutes immediately after morning dosing of Tofacitinib or CsA on day of GFR evaluation. Blood samples for iohexol (3 millilitres [mL] each to provide a minimum of 1 mL serum) were collected into appropriately labeled tubes containing no additives at 120, 180, 240, and 300 minutes after the end of the iohexol IV bolus. A normal GFR is greater than (>) 90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (<) 15 mL/min indicated kidney failure.

  4. Percentage of Participants With Progression of Chronic Allograft Lesions at Month 36 [ Time Frame: Month 36 ]
    Progression of chronic allograft lesions was defined as an increase in the Banff chronicity score (Banff-CS) in biopsy from the implantation (baseline) biopsy in a given participant. Banff-CS was the sum of the Banff scores for the 4 chronic basic lesions (allograft glomerulopathy [cg] + interstitial fibrosis [ci] + tubular atrophy [ct] + vascular intimal thickening [cv]). The Banff-CS ranged from 0-12, higher score indicated greater lesions and Month 36 Banff-CS greater than the implantation biopsy score indicated progression of lesions.

  5. Kaplan-Meier Analysis of Percentage of Participants With First Biopsy Proven Acute Rejection (BPAR) by Visit [ Time Frame: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]
    BPAR was category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification. The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits.

  6. Kaplan-Meier Analysis of Percentage of Participants With Treated Clinical Acute Rejection by Visit [ Time Frame: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]
    Treated clinical acute rejection was defined as an acute rejection episode that was diagnosed based on local biopsy readout and received anti-rejection treatment. The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits.


Secondary Outcome Measures :
  1. Kaplan-Meier Analysis of Percentage of Participants With Efficacy Failure by Visit [ Time Frame: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]
    Efficacy failure was the first occurrence of BPAR diagnosed by the central pathologist or graft loss including participant death. BPAR (category acute rejection) was interpreted by the central blinded pathologist according to the Banff 97 working classification. The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits.

  2. Kaplan-Meier Analysis of Percentage of Participants With Combined Banff Rejection by Visit [ Time Frame: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]
    Banff 97: standard classification for scoring and classifying rejection of kidney transplant biopsies in 6 diagnostic categories: normal, antibody-mediated rejection, borderline changes: 'suspicious' for acute cellular rejection, acute/active cellular rejection, chronic/sclerosing allograft nephropathy, and other. Combined Banff rejection was calculated from categories of antibody-mediated rejection (Category 2) plus borderline changes (Category 3) plus acute rejection (Category 4), as interpreted by the central pathologist. The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits.

  3. Kaplan-Meier Analysis of Percent of Participants With Graft Survival With Death Censored by Visit [ Time Frame: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]
    Graft loss was defined as graft nephrectomy, subject death, retransplantation, or return to dialysis for at least 6 consecutive weeks. The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits. Included data up to 2 months postdose in the clinical Follow-up visit.

  4. Kaplan-Meier Analysis of Percentage of Participants Surviving by Visit [ Time Frame: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]
    The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits. Included data up to 2 months postdose in the clinical Follow-up visit.

  5. Percentage of Participants Discontinuing From the Study [ Time Frame: Months 12 through 72. ]
    Discontinuations were due to any reason including those occurring as a result of protocol Amendments 3 and 4.

  6. Least Squares Means of Total Serum Cholesterol Levels (Milligrams Per Deciliter [mg/dL]) by Visit [ Time Frame: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]
    Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. A first-order autoregressive variance-covariance structure was used.

  7. Least Squares Means of Total Serum Low Density Lipoprotein (LDL) Cholesterol Levels (mg/dL) by Visit [ Time Frame: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]
    Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. A first-order autoregressive variance-covariance structure was used.

  8. Least Squares Means of Total Serum High Density Lipoprotein (HDL) Cholesterol Levels (mg/dL) by Visit [ Time Frame: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]
    Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. A first-order autoregressive variance-covariance structure was used.

  9. Least Squares Means of Total Serum Triglycerides (mg/dL) by Visit [ Time Frame: Month 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]
    Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. A first-order autoregressive variance-covariance structure was used.

  10. Mean Absolute Neutrophil Counts (ANC) (Kelvin Per Millimeter Cubed [K/mm^3]) by Visit [ Time Frame: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 and Follow-up ]
    Follow-up visit included Month 74 visit for completers and 2-month postdose visit for early withdrawals.

  11. Mean Hemoglobin (Hgb) (Grams Per Deciliter [g/dL]) by Visit [ Time Frame: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 and Follow-up ]
    Follow-up visit included Month 74 visit for completers and 2-month postdose visit for early withdrawals.

  12. Mean Glycosylated Hemoglobin (HBA1c) (Percent [%]) by Visit [ Time Frame: Months 24, 36, 48, 60, 72 ]
    HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. The normal range for the HbA1c test is between 4% and 5.6%. HbA1c levels between 5.7% and 6.4% indicate increased risk of diabetes and levels of 6.5% or higher indicate diabetes.

  13. Least Squares Means of Fasting Serum Glucose Levels (mg/dL) by Visit [ Time Frame: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]
    Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. A compund symmetry variance-covariance structure was used.

  14. Percentage of Participants by Proteinuria Category by Visit [ Time Frame: Months 24, 36, 48, 60, 72 and Follow-up ]
    Proteinuria was defined as the presence of an excess of serum proteins in the urine. Normal value of proteinuria is below 0.15 grams per 24 hours (g/24 hr). Follow-up visit included Month 74 visit for completers and 2-month postdose visit for early withdrawals.

  15. Least Square Means of Estimated GFR Calculated Using the Nankivell Equation by Visit [ Time Frame: Month 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]

    GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using Nankivell formula, where:

    Creatinine clearance (mL/min) = 6.7/serum creatinine (millimols per litre [mmol/L]) - serum urea (mmol/dL)/2 + actual body weight (kilograms [kg])/4 - 100/Height (metres [m])^2 + (35 for male or 25 for female).

    A normal GFR for adults is > 90 mL/min. Lower values indicate poor kidney function. A GFR <15 is consistent with kidney failure.

    Model contained treatment, visit and treatment by visit interaction as fixed effects. An unstructured variance-covariance structure was used.


  16. Least Squares Means of Estimated GFR Calculated Using the Cockcroft-Gault Equation by Visit [ Time Frame: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]

    GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR (mL/min) was calculated using Cockcroft-Gault equation. GFR by Cockcroft-Gault equation= body weight (kg)*(140 minus age in years) divided by (72*serum creatinine [mg/dL]). For females value obtained was multiplied by 0.85. A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.

    Model contained treatment, visit and treatment by visit interaction as fixed effects. An unstructured variance-covariance structure was used.


  17. Least Squares Means of Estimated GFR (eGFR) (mL/Min/1.73 Square Meter [m^2]) Calculated by the Modification of Diet in Renal Disease (MDRD) Equation With Last Observation Carried Forward (LOCF) Plus Imputation (eGFR=0 for Graft Loss/Death) by Visit [ Time Frame: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 ]

    GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using MDRD equation. GFR (mL/min/1.73 m^2) by MDRD equation = 170 * (serum creatinine [mg/dL])^(-0.999) * (age in years)^(-0.176) * (0.762 if female) * (1.18 if black) * (blood urea nitrogen concentration [mg/dL])^(-0.170) * (serum albumin concentration [g/dL])^(0.318). A normal GFR is >90 mL/min/1.73 m^2, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min/1.73 m^2 indicated kidney failure.

    Model contained treatment, visit and treatment by visit interaction as fixed effects. An unstructured variance-covariance structure was used.


  18. Least Squares Means of Short Form 36 Version 2 (SF-36 V2) Component and Domain Scores at Months 24 and 36 [ Time Frame: Months 24, 36 ]
    SF-36 v2 is a self-administered 36-item generic health status measure with 8 general health concepts which are the weighted sums of the questions in their section: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health. Each scale is transformed into a 0 (minimum) to 100 (maximum) scale on the assumption each question carries equal weight. These concepts were also summarized into 2 summary scores; Physical Component Summary and Mental Component Summary (both a 0-100 scale). The 8 subscales, 2 summary scores and transition Question 2 (TR Scale, measured on a scale of 1 [minimum] to 5 [maximum]) were subjected to analysis. Higher domain, summary scores, and TR scale scores indicate better health status. Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. First-order autoregressive variance-covariance structure was used.

  19. Least Squares Means of End-Stage Renal Disease (ESRD) Symptom Checklist (SCL) -Transplantation Modules at Months 24 and 36 [ Time Frame: Months 24, 36 ]

    ESRD-SCL: a 43-item disease specific self-administered questionnaire. Participants' rated the question "At the moment,how much do you suffer?" for each item on a 5 point scale, range (Ra) from 0 (not at all) to 4 (extremely). Consisted of 6 subscales: Cardiac and Renal (CR) dysfunction; Ra 0 to 28, Increased(In) Growth of Gum and Hair (IGGH); Ra 0 to 20, Limited Cognitive Capacity (LCC); Ra 0 to 32, Limited Physical Capacity (LPC); Ra 0 to 40, Side Effects (SEs) of Corticosteroids; Ra 0 to 20, Transplantation Associated Psychological Distress (TAPD); Ra 0 to 32. Total Score: 0 to 172, higher scores indicate greater dysfunction.

    Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. A first-order autoregressive variance-covariance structure was used.


  20. Least Squares Means of Severity of Dyspepsia Assessment (SODA) Subscales at Months 24 & 36 [ Time Frame: Months 24, 36 ]

    SODA:17-item health scale, assessed participant-reported perceptions of dyspepsia; consists of 3 subscales: Pain Intensity (PI, 6-items to assess pain and intensity of abdominal discomfort; Range: 2 to 47, higher score indicates greater pain and abdominal discomfort), Non-Pain Symptoms (NPS, 7-items to assess severity and impact of non-pain symptoms: burping/belching, heartburn, bloating, flatulence, sour taste, nausea, and bad breath; Range: 7 to 35, higher scores indicate increased symptom severity and influence), and Satisfaction (4-items to assess degree of satisfaction with abdominal discomfort; Range: 2 to 23, higher scores indicate more satisfaction).

    Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. A first-order autoregressive variance-covariance structure was used.


  21. Mean Trough Levels of Tofacitinib by Visit [ Time Frame: Months 18 and 24 (-2 hours, predose, 1 hour, 2 hours), Month 30 (predose, 1 hour and 2 hours), Month 36 (predose, 1, 2, and 4 hours), Months 42, 48, 54, 60, 66, 72 (predose and 2 hours) ]
    The dates and times were recorded for the 6 doses of tofacitinib administered before each scheduled pharmacokinetic (PK) sampling. The participant was instructed to follow a 12 hourly schedule for these 6 doses of tofacitinib, with each dose administered within 1 hour of the scheduled time. Trough samples were collected 0 to 10 minutes prior to the morning dose. 1 hour postdose samples were required within 10 minutes of the nominal time point. Samples taken at -2 hours predose and at time points >1 hour post dose were required within 30 minutes of the nominal time point.

  22. Mean Trough Levels of Cyclosporine by Visit [ Time Frame: Predose: Months 18, 24, 36, 48, 60, 72 ]
    All CsA samples were taken predose (collected 0 to 10 minutes prior to the morning dose).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who successfully completed Study A3921030

Exclusion Criteria:

  • Subjects who are on the waiting list for a second kidney transplant or any non-renal organ transplants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00658359


  Hide Study Locations
Locations
United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Cedars-Sinai MedicalCenter
Los Angeles, California, United States, 90048
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States, 90095
UCLA Medical Center
Los Angeles, California, United States, 90095
Stanford School of Medicine
Palo Alto, California, United States, 94304
Stanford University Medical Center
Palo Alto, California, United States, 94305
Balboa Institute of Transplantation
San Diego, California, United States, 92123
California Institute of Renal Research
San Diego, California, United States, 92123
Sharp Memorial Hospital
San Diego, California, United States, 92123
California Pacific Medical Center - Pacific Campus
San Francisco, California, United States, 94115
California Pacific Medical Center
San Francisco, California, United States, 94115
UCSF Medical Center - Long Hospital
San Francisco, California, United States, 94143
USCF Medical Center - Connie Frank Transplant Center
San Francisco, California, United States, 94143
United States, Colorado
University of Colorado Denver
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale-New Haven Hospital
New Haven, Connecticut, United States, 06504
Yale Physicians Building
New Haven, Connecticut, United States, 06510
United States, Florida
University Of Florida
Gainesville, Florida, United States, 32610
Tampa General Hospital
Tampa, Florida, United States, 33606
United States, Illinois
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States, 60611
NUCATS's Clinical Research Unit
Chicago, Illinois, United States, 60611
United States, Michigan
University of Michigan Health System
Ann Arbor, Michigan, United States, 48109
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Hurley Medical Center
Flint, Michigan, United States, 48503
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, North Carolina
Investigational Drug Services (IDS) / UNC Healthcare
Chapel Hill, North Carolina, United States, 27514
Transplant Clinic/UNC Heathcare
Chapel Hill, North Carolina, United States, 27514
UNC Department of Surgery, Clinical Trials Consortium
Chapel Hill, North Carolina, United States, 27599-7211
UNC Department of Surgery/Abdominal Transplant Division
Chapel Hill, North Carolina, United States, 27599-7211
Division of Pharmacotherapy, School of Pharmacy, University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599-7360
University of North Carolina, Department of Medicine/Nephrology
Chapel Hill, North Carolina, United States, 27599
United States, Pennsylvania
Drexel University College of Medicine - Hahnemann University Hospital
Philadelphia, Pennsylvania, United States, 19102
Hahnemann University Hospital
Philadelphia, Pennsylvania, United States, 19102
United States, South Carolina
Medical University of South Carolina, Department of Transplantation Surgery
Charleston, South Carolina, United States, 29425
Nephrology Clinic
Charleston, South Carolina, United States, 29425
United States, Texas
Dallas Transplant Institute
Dallas, Texas, United States, 75204
Annette C. and Harold C. Simmons Transplant Institute at Baylor University Medical Center
Dallas, Texas, United States, 75246
Baylor University Medical Center
Dallas, Texas, United States, 75246
Australia, New South Wales
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia, 2050
Westmead Hospital, Department of Renal Medicine
Westmead, New South Wales, Australia, 2145
Australia, South Australia
Central Northern Adelaide Renal and Transplantation Service
Adelaide, South Australia, Australia, 5000
The Queen Elizabeth Hospital
Woodville, South Australia, Australia, 5011
Australia, Victoria
Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050
Belgium
Hopital Erasme
Anderlecht, Brussels, Belgium, 1070
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Belgium, 3000
Brazil
Irmandade Santa Casa de Misericordia de Porto Alegre
Porto Alegre, RS, Brazil, 90020-090
Hospital do Rim e Hipertensao
Sao Paulo, SP, Brazil, 04038-002
Ambulatorio Pos Transplante do Hospital do Rim a Hipertensao
Sao Paulo, SP, Brazil, 04039-033
Hospital do Rim e Hipertensao
Sao Paulo, Brazil, 04038-002
Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
Czechia
Institut Klinicke a Experimentalni Mediciny
Praha 4 Krc, Czechia, 140 21
France
Hopital Necker
Paris Cedex 15, France, 75743
CHRU de Nancy-Brabois - Service de Nephrologie
Vandoeuvre Les Nancy, France, 54500
Germany
Charite - Universitatsmedizin Berlin
Berlin, Germany, 10117
Italy
Istituto di Clinica Chirurgica, Universita Cattolica del Sacro Cuore
Roma, RM, Italy, 00168
Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola Malpighi
Bologna, Italy, 40138
Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Department of Surgery, Yonsei University College of Medicine Severance Hospital
Seoul, Korea, Republic of, 120-752
Asan Medical Center, Department of Surgery
Seoul, Korea, Republic of, 138-736
Netherlands
Erasmus Medisch Centrum
Rotterdam, Netherlands, 3015 GD
Norway
Oslo universitetssykehus HF- Rikshospitalet
Oslo, Norway, 0372
Poland
Akademicki Szpital Kliniczny im. J. Mikulicza - Radeckiego we Wroclawiu
Wroclaw, Poland, 50-556
Portugal
Hospitais da Universidade de Coimbra, EPE
Coimbra, Portugal, 3000-075
Hospital Curry Cabral
Lisboa, Portugal, 1069-166
Spain
Hospital Universitari de Bellvitge
Hospitalet de Llobregat, Barcelona, Spain, 08907
Hospital Clinic i Provincial de Barcelona
Barcelona, Spain, 08036
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00658359     History of Changes
Other Study ID Numbers: A3921050
2008-002345-23 ( EudraCT Number )
First Posted: April 15, 2008    Key Record Dates
Results First Posted: February 23, 2018
Last Update Posted: February 23, 2018
Last Verified: February 2018

Keywords provided by Pfizer:
Immunosuppression
JAK inhibitor
kidney transplantation

Additional relevant MeSH terms:
Cyclosporins
Cyclosporine
Tofacitinib
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors
Protein Kinase Inhibitors